Toxoplasmosis is a worldwide neglected tropical disease caused by the intracellular protozoan named *Toxoplasma gondii* \[[@b1-kjp-54-1-93]\]. Humans usually become infected through the ingestion of undercooked meat containing the encysted stage of the parasite (tissue cysts) or food and water contaminated with cat faces containing oocysts \[[@b2-kjp-54-1-93]\]. Transmission also occurs due to the congenital infection through the placenta \[[@b3-kjp-54-1-93]\]. In addition, people may get infected by blood transfusion or organ transplantation \[[@b4-kjp-54-1-93]\].

*T. gondii* infections occur throughout the world \[[@b1-kjp-54-1-93]\]. Epidemiological evidence shows that one third of the world population has been in contact with the parasite; however, the infection rate varies greatly by country. The foci of high prevalence are detected in Latin America (about 50-80%), parts of Eastern/Central Europe (about 20-60%), the Middle East (about 30-50%), parts of Southeast Asia (about 20-60%), and Africa (about 20-55%), while a trend towards lower seroprevalence is observed in many European countries and USA (10.2-11.8%) \[[@b5-kjp-54-1-93]\]. An estimated 80% of the subjects infected with the parasite is asymptomatic, as tissue cysts can persist indefinitely during the host's life \[[@b6-kjp-54-1-93]\]; however, the infection is life-threatening and causes substantial neurologic damage if an individual becomes immunocompromised, such as HIV/AIDS patients, and organ transplantation recipients \[[@b7-kjp-54-1-93]\]. In pregnant women, *T. gondii* infection may lead to devastating disease for the fetus and newborn infant, later impact on the child\'s health and development and potentially on his/her later productivity \[[@b8-kjp-54-1-93]\]. In the current study, we investigated the seroprevalence of *T. gondii* infection in subjects infected with HIV/AIDS in eastern China, and compared it with that detected in drug users and healthy population.

The blood samples of 259 HIV/AIDS patients were collected from Wuxi, Jiangsu province, eastern China, and all diagnoses were confirmed by Western blotting assay. Total 90 serum samples were collected from drug addicts in Wuxi Municipal Compulsory Drug Rehabilitation Center (Wuxi, China), and all these subjects had a history of intravenous drug use, while the sera collected from 85 healthy individuals that were provided by the Wuxi Municipal Center for Disease Control and Prevention, China (Wuxi, China) served as controls. This study was approved the Institutional Review Committee of Wuxi No. 9 People's Hospital (XJY2011-0128). Signed informed consent was obtained from all participants, following the detailed description of the potential purpose of this study.

Serum samples were assayed for anti-*Toxoplasma* IgG and IgM antibodies using an ELISA kit (Zhuhai Haitai Biological Pharmaceuticals Co., Zhuhai, China) following the manufacturer\'s instructions. Absorbance was measured at 450 nm (*A*~450~) with a Bio-Cell™ microtiter plate reader (BioTek; Winooski, Vermont, USA). The cut-off value was 2.5 times than the mean absorbance value for controls. Positives were considered as such when *A*~450~ values were higher than the cut-off.

The CD4^+^ T-lymphocyte count in the blood samples from HIV/AIDS patients was determined using a FACSCalibur™ flow cytometer (BD; San Jose, California, USA). All patients were grouped according to the CD4^+^ T-lymphocyte count. CD4^+^ T-lymphocyte count of ≥500 cells/ml was defined as normal immune function; a count of \<500 cells/ml and ≥200 cells/ml was considered immunocompromised; a count of 200 cells/m and ≥50 cells/ml was considered severely immunocompromised, while a count of \<50 cells/ml was defined as advanced AIDS \[[@b9-kjp-54-1-93]\]. The seroprevalence of *T. gondii* infection was detected and compared among various groups of HIV/AIDS patients.

All data were double-entered into Microsoft Excel 2007 (Microsoft Corporation; Redmond, Washington, USA) and all statistical analyses were performed using the statistical software SPSS version 17.0 (SPSS Inc., Chicago, Illinois, USA). Differences of proportions were tested for statistical significance with the chi-square test. A *P*-value \<0.05 was considered statistically significant.

Our findings showed the highest seroprevalence of anti-*Toxoplasma* IgG antibody in the HIV/AIDS patients, while the lowest seroprevalence was found in intravenous drug users. The frequency of anti-*Toxoplasma* IgG antibody was significantly greater in HIV/AIDS patients than in intravenous drug users (χ^2^=4.18, *P*\<0.05), with no other significant differences observed. There was no significant difference in the seroprevalence of anti-*Toxoplasma* IgM antibody among all participants ([Table 1](#t1-kjp-54-1-93){ref-type="table"}).

Of the 259 HIV/AIDS patients, 50 cases (19.3%) had normal immune function, 129 cases (49.8%) were immunocompromised, 73 cases (28.2%) were severely immunocompromised, and 7 cases (2.7%) had advanced AIDS. A total of 201 cases (80.7%) had immune dysfunctions. Among all HIV/AIDS patients, 15 men (7.7%) and 10 women (15.9%) were positive for anti-*T. gondii* IgG antibody; however, no significant difference was detected in the seroprevalence of anti-*Toxoplasma* IgG antibody between males and females. The frequency of anti-*Toxoplasma* IgG antibody was 8%, 13.2%, 5.5%, and 0% in patients with normal immune functions, immunocompromised patients, severely immunocompromised patients, and advanced AIDS patients, respectively ([Table 2](#t2-kjp-54-1-93){ref-type="table"}). There were only 3 immunocompromised patients positive to anti-*T. gondii* IgM antibody. A higher prevalence of anti-*Toxoplasma* IgG antibody was detected in women with HIV/AIDS (15.9%) than in men (7.7%); however, no significant difference was observed (*P*\>0.05). In immunocompromised subjects, the prevalence of anti-*Toxoplasma* IgG antibody was significantly greater in women (25%) than in men (9.3%) (χ^2^=5.2, *P*\<0.05), while no other gender differences were found ([Table 2](#t2-kjp-54-1-93){ref-type="table"}).

Although *T. gondii* infection has a high prevalence, it does not cause apparent syndromes or only induces mild self-limited diseases in subjects with normal immune functions \[[@b6-kjp-54-1-93]\]. The long-term latent infection, however, may be activated and lead to pathological changes after the host's immune function is impaired \[[@b10-kjp-54-1-93]\]. In immunocompromised subjects, the infection may expand all through the body and cause severe visceral toxoplasmosis \[[@b11-kjp-54-1-93]\]. Toxoplasmosis is therefore considered as a consequence of recurrence of a previously latent infection in most AIDS patients, and the prevalence was estimated to be 20-47% in HIV-seropositive subjects without preventive interventions \[[@b12-kjp-54-1-93]\].

A high seroprevalence of anti-*T. gondii* IgG antibody has been reported in HIV-infected subjects \[[@b13-kjp-54-1-93]-[@b15-kjp-54-1-93]\]. To our knowledge, however, there is little information on the prevalence of *T. gondii* infection in HIV/AIDS patients in eastern China. In the current study, the seroprevalence of anti-*Toxoplasma* IgG antibody was 9.7% in HIV/AIDS patients, which was higher than in intravenous drug users and healthy persons. Our findings demonstrate a high seroprevalence of *T. gondii* infection in HIV/AIDS patients, suggesting that HIV-infected populations should be protected from *T. gondii* infection to reduce the prevalence and morbidity and burden of the disease.

The detection of anti-*Toxoplasma* IgM antibody demonstrates the presence of a recent infection for the first time \[[@b16-kjp-54-1-93]\]. In this study, anti-*T. gondii* IgM antibody was detected in only 3 (1.2%) immunocompromised patients, who still had some immune functions; however, 80.7% of the HIV/AIDS patients developed immune function impairments at various degrees, inferring the possibility of recurrence of previously latent *T. gondii* infection in most patients. Our findings demonstrated a high prevalence of *T. gondii* infection and the development of immune function impairments at various levels in HIV/AIDS patients in China. It is therefore suggested that the parasite *T. gondii*, as a major opportunistic pathogen, be involved in the detection and monitoring of HIV/AIDS based on detection of IgG antibodies.

The subgroup analysis of CD4^+^ T-lymphocyte counts revealed the highest prevalence of anti-*T. gondii* IgG antibodies in immunocompromised patients (CD4^+^ T-lymphocyte count \<500 cells/ml and ≥200 cells/ml), followed by patients with normal immune functions (cell count ≥500 cells/ml), while no seropositives were detected in advanced AIDS patients (cell count \<50 cells/ml). In addition, the present study showed a higher seroprevalence of anti-*T. gondii* IgG antibody in women than men. Such a finding may be associated with activation of the cyst or pseudocyst, which is easily induced by the high estrogen level \[[@b17-kjp-54-1-93]\].

Currently, the 3 major routes for HIV transmission (sexual contact, exposure to infected body fluids or tissues, and vertical transmission) are all present in China \[[@b18-kjp-54-1-93]\]; however, intravenous drug users will be the population at highest risk of the infection \[[@b19-kjp-54-1-93]\]. In the current study. the prevalence of anti-*T. gondii* IgG antibody was 2.2% in drug users, which was significantly lower than that in HIV/AIDS patients (7.7%) and even lower than in healthy controls (4.7%), indicating that transmission through blood is not a major route for *T. gondii* transmission. In addition, the drug users still have comparative normal immune systems, and drug uses cause the alteration of the lifestyle, which leads to a low opportunity to have opportunistic infections.

In conclusion, the results of this study demonstrate a high seroprevalence of *T. gondii* infection in HIV/AIDS patients, and the risk of relapse of a previously latent infection increases with the reduction in the host's immune function, notably in immunocompromised subjects. The surveillance of *T. gondii* infection is suggested in HIV/AIDS patients for the early diagnosis of the disease, and preventive therapy may be given to those positive for anti-*T. gondii* specific IgG antibody, based on the CD4^+^ T-lymphocyte counts, to slow the progression of the disease. Since the immune functions of the HIV/AIDS patients are progressively impaired, the detection of specific anti-*T. gondii* IgG antibody may not coincide with the real status of *T. gondii* infection at the middle and late stages of HIV infection. The addition of PCR assay to routine antibody-based immunological diagnosis may more accurately reflect the real *T. gondii* infection in HIV/AIDS patients \[[@b20-kjp-54-1-93]\].
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###### 

Frequency of anti-*Toxoplamsa* IgG and IgM antibodies

  Subjects                 Anti-*Toxoplasma* IgG antibody^[a](#tfn1-kjp-54-1-93){ref-type="table-fn"}^   Anti-*Toxoplasma* IgM antibody^[b](#tfn2-kjp-54-1-93){ref-type="table-fn"}^         
  ------------------------ ----------------------------------------------------------------------------- ----------------------------------------------------------------------------- ----- -----
  HIV/AIDS patients        259                                                                           9.7                                                                           259   1.2
  Intravenous drug users   90                                                                            2.2                                                                           90    0
  Healthy controls         85                                                                            4.7                                                                           85    1.2

The prevalence of anti-*Toxoplasma* IgG antibody was significantly greater in HIV/AIDS patients than that in intravenous drug users (*P*\<0.05), with no other significant differences observed (*P*\>0.05).

There was no significant difference in the prevalence of anti-*Toxoplasma* IgM antibody among the three types of study subjects (*P*\>0.05).

###### 

Frequency of anti-*Toxoplamsa* IgG antibody in HIV/AIDS patients with different CD4+ T-lymphocyte counts

  Immune function                                                           Men   Women   Total                
  ------------------------------------------------------------------------- ----- ------- ------- ------ ----- ------
  Normal^[a](#tfn3-kjp-54-1-93){ref-type="table-fn"}^                       40    10      10      0      50    8
  Immunocompromised^[b](#tfn4-kjp-54-1-93){ref-type="table-fn"}^            97    9.3     32      25     129   13.2
  Severely immunocompromised^[c](#tfn5-kjp-54-1-93){ref-type="table-fn"}^   53    3.8     20      10     73    5.5
  Advanced AIDS^[d](#tfn6-kjp-54-1-93){ref-type="table-fn"}^                6     0       1       0      7     0
  Total                                                                     196   7.7     63      15.9   259   9.7

*P*\>0.05, men vs women.

*P*\<0.05, men vs women.

*P*\>0.05, men vs women.

*P*\>0.05, men vs women.
